Marksans Pharma’s board has approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Q3 2026). The statutory auditors have issued unmodified opinions on both sets of results. The company’s statutory auditors, M S K A & Associates, converted to a Limited Liability Partnership, effective January 12, 2026, now known as MSKA & Associates LLP.
Financial Performance Overview
The board of Marksans Pharma has officially approved the unaudited financial results for Q3 2026, ending December 31, 2025. Both standalone and consolidated results have been reviewed, with statutory auditors issuing unmodified opinions.
Standalone Financial Highlights
Key figures from the standalone unaudited financial results include:
- Revenue from Operations: ₹3,397.29 million
- Profit Before Tax: ₹821.16 million
- Profit After Tax: ₹609.12 million
- Total Comprehensive Income: ₹618.46 million
Consolidated Financial Highlights
Key figures from the consolidated unaudited financial results include:
- Revenue from Operations: ₹7,544.27 million
- Profit Before Tax: ₹1,506.24 million
- Profit After Tax: ₹1,136.90 million
- Total Comprehensive Income: ₹1,329.03 million
Auditor Transition
Marksans Pharma’s statutory auditors, formerly known as M SK A & Associates, have transitioned to a Limited Liability Partnership. Effective January 12, 2026, they will operate under the name MSKA & Associates LLP, Chartered Accountants. The firm’s new ICAI Firm Registration Number (FRN) is 105047W/W101187.
Subsidiary Updates
Marksans Pharma has formed two new wholly-owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland, incorporated on January 16, 2026, and Marksans (Canada) Inc. in Canada, incorporated on January 22, 2026.
Source: BSE
